While Pfizer's market cap and dividends are at risk, Novo has a strong competitive position in GLP-1 TAM. Read why I prefer ...

The British government on Saturday announced over 1.25 billion pounds ($1.69 billion) in fresh investment from major US ...

Exagen has surged on record revenue and pipeline promise, but faces reimbursement, execution, and valuation risks. Find out ...